Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of empagliflozin administered orally once daily in postprandial
glucose and 24-hour glycaemic variability compared to placebo given for 4 weeks as
mono-therapy in Japanese patients with type 2 diabetes mellitus with insufficient glycaemic
control on no antidiabetic treatment.